# A 3-Week Inpatient Rehabilitation Programme Improves Body Composition in People with Cystic Fibrosis with and Without Elexacaftor/Tezacaftor/Ivacaftor Therapy

**Authors:** Jana Koop, Wolfgang Gruber, Franziska A. Hägele, Kristina Norman, Catrin Herpich, Stefan Dewey, Christian Falkenberg, Olaf Schnabel, Burkhard Weisser, Mario Hasler, Anja Bosy-Westphal

PMC · DOI: 10.3390/nu17152439 · Nutrients · 2025-07-25

## TL;DR

A 3-week inpatient rehab program improved body composition in cystic fibrosis patients, with similar results whether they used ETI therapy or not.

## Contribution

The study shows that ETI therapy does not enhance body composition gains during rehab compared to non-ETI patients.

## Key findings

- The program increased BMI and fat-free mass index in cystic fibrosis patients.
- ETI users had similar body composition changes as non-ETI users despite differences in appetite markers.
- Higher rates of pancreatic insufficiency in ETI users may explain similar outcomes.

## Abstract

Background: The introduction of cystic fibrosis transmembrane conductance regulator modulators, especially the triple therapy elexacaftor, tezacaftor, ivacaftor (ETI), has improved outcomes in people with cystic fibrosis (pwCF), reducing underweight but increasing overweight rates. Objectives: This study investigates the effect of ETI on appetite control, body composition, and energy balance during a 3-week inpatient rehabilitation programme with regular exercise. Methods: In 54 pwCF (38 on ETI, 16 without ETI), changes in body composition (fat mass index, FMI; fat-free mass index, FFMI) and energy balance (calculated from body composition changes) were assessed. Appetite control was evaluated via plasma peptide YY (PYY) levels and post-exercise meal energy intake. Results: The programme significantly increased BMI (+0.3 ± 0.1 kg/m2; CI 0.1–0.4) and energy balance (+4317 ± 1976 kcal/3 weeks), primarily through FFMI gains (+0.3 ± 0.1 kg/m2; CI 0.1–0.4). Despite higher post-exercise meal energy intake and a tendency towards lower PYY levels in the ETI group, changes in body composition and energy balance did not differ between groups. This is explained by a higher prevalence of exocrine pancreatic insufficiency in the ETI group (92% vs. 50%, p < 0.001). Small sample sizes limit the interpretation of data on appetite control and energy intake. Conclusions: A 3-week inpatient rehabilitation programme improved body composition in pwCF, without resulting in a more positive energy balance with ETI therapy. This is due to a higher prevalence of pancreatic insufficiency in this group.

## Linked entities

- **Proteins:** Pyy (peptide YY)
- **Chemicals:** elexacaftor (PubChem CID 134587348), tezacaftor (PubChem CID 46199646), ivacaftor (PubChem CID 16220172)
- **Diseases:** cystic fibrosis (MONDO:0009061)

## Full-text entities

- **Genes:** CFTR (CF transmembrane conductance regulator) [NCBI Gene 1080] {aka ABC35, ABCC7, CF, CFTR/MRP, MRP7, TNR-CFTR}, PYY (peptide YY) [NCBI Gene 5697] {aka PYY-I, PYY1}
- **Diseases:** overweight (MESH:D050177), Cystic Fibrosis (MESH:D003550), exocrine pancreatic insufficiency (MESH:D010188), underweight (MESH:D013851)
- **Chemicals:** ETI (-), Elexacaftor (MESH:C000629074), Tezacaftor (MESH:C000625213), Ivacaftor (MESH:C545203)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12348923/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12348923/full.md

## References

76 references — full list in the complete paper: https://tomesphere.com/paper/PMC12348923/full.md

---
Source: https://tomesphere.com/paper/PMC12348923